See Novo Nordisk's analyst price targets ($45) vs the current share price.
Get informed when a big investor buys or sells
+ Follow$37.53
3 analysts in the last 4 months
High: $47 | Low: $40
No recommendations in the last 4 months.
Novo Nordisk posts a target price of $45. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
A target price of $45 for NVO means covering analysts, on average, see the stock 19.0% upside of $37.53 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.
Context for NVO's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Novo Nordisk's other metric pages and overview cover the third.
Judging Novo Nordisk against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $45 here, then scan peer and history charts to see if the gap is persistent.